Clinical transplantation and tolerance: Are we there yet?

International Journal of Organ Transplantation Medicine

Volumn 5, Issue 4, 2014, Pages 137-145

  Saidi, R F ^a   Hejazii Kenari, S K ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Childhood; Immune system; Immunosuppression; Kidney disease; Neoplasms; Tolerance; Transplantation

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; TACROLIMUS; THYMOCYTE ANTIBODY;

ALLERGIC REACTION; ANAPHYLAXIS; ARTICLE; BONE MARROW SUPPRESSION; BRONCHOSPASM; CHOLESTASIS; CHRONIC KIDNEY DISEASE; CUSHINGOID SYNDROME; CYTOMEGALOVIRUS; DIABETES MELLITUS; FAILURE TO THRIVE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GRAFT RECIPIENT; GRAFT REJECTION; GROWTH DISORDER; GROWTH RETARDATION; HEARING IMPAIRMENT; HEPATIC NODULAR HYPERPLASIA; HIRSUTISM; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIFE EXPECTANCY; LONG TERM CARE; LYMPHOCYTE DEPLETION; LYMPHOCYTOPENIA; MOUSE; NEOPLASM; NEPHROTOXICITY; NEUROTOXICITY; NODULAR HYPERPLASIA; NONHUMAN; ORGAN TRANSPLANTATION; OSTEOPENIA; QUALITY OF LIFE; SCLEROSIS; SERUM SICKNESS; SHOCK; T CELL DEPLETION; VIRUS REACTIVATION; WOUND HEALING;

EID: 84913588147     PISSN: 20086490     EISSN: 20086482     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Feng S. Long-term management of immunosuppression after pediatric liver transplantation: is minimization or withdrawal desirable or possible or both? Curr Opin Organ Transplant 2008;13:506-12.
2. Londoño M-C, Danger R, Giral M, et al. A need for biomarkers of operational tolerance in liver and kidney transplantation. Am J Transplant 2012;12:1370-7.
3. Saidi RF. Current status of liver transplantation. Arch Iran Med 2012;15:772-6.
4. Saidi RF, Markmann JF, Jabbour N, et al. The faltering solid organ donor pool in the United States (2001-2010). World J Surg 2012;36:2909-13.
5. Bucuvalas JC, Alonso E, Magee JC, et al. Improving long-term outcomes after liver transplantation in children. Am J Transplant 2008;8:2506-13.
6. Horslen S, Barr ML, Christensen LL, et al. Pediatric transplantation in the United States, 1996-2005. Am J Transplant 2007;7:1339-58.
7. Tredger JM, Brown NW, Dhawan A. Immunosuppression in pediatric solid organ transplantation: opportunities, risks, and management. Pediatr Transplant 2006;10:879-92.
8. Traum AZ, Kawai T, Vacanti JP, et al. The need for tolerance in pediatric organ transplantation. Pediatrics 2008;121:1258-60.
9. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 1998;66:1736-40.
10. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-40.
11. Arora-Gupta N, Davies P, McKiernan P, Kelly DA. The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation. Pediatr Transplant 2004;8:145-50.
12. Fine RN. Renal function following liver transplantation in children. Pediatr Transplant 2005;9:680-4.
13. Midtvedt K, Hjelmesaeth J, Hartmann A, et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 2004;15:3233-9.
14. Li L, Wozniak LJ, Rodder S, et al. A common peripheral blood gene set for diagnosis of operational tolerance in pediatric and adult liver transplantation. Am J Transplant 2012;12:1218-28.
15. Traum AZ, Ko DS, Kawai T. The potential for tolerance in pediatric renal transplantation. Curr Opin Organ Transplant 2008;13:489-94.
16. Koshiba T, Li Y, Takemura M, et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol 2007;17:94-7.
17. Ohe H, Waki K, Yoshitomi M, et al. Factors affecting operational tolerance after pediatric livingdonor liver transplantation: impact of early posttransplant events and HLA match. Transpl Int 2012;25:97-106.
18. Pearl JP, Preston E, Kirk AD. Tolerance: is it achievable in pediatric solid organ transplantation? Pediatr Clin North Am. 2003;50:1261-81
19. Stuber ML. Psychiatric issues in pediatric organ transplantation. Child Adolesc Psychiatr Clin N Am 2010;19:285-300.
20. Evans RW, Applegate WH, Briscoe DM, et al. Costrelated immunosuppressive medication nonadherence among kidney transplant recipients. Clin J Am Soc Nephrol 2010;5:2323-8.
21. Girlanda R, Kirk AD. Frontiers in nephrology: immune tolerance to allografts in humans. J Am Soc Nephrol 2007;18:2242-51.
22. Wieërs G, Gras J, Bourdeaux C, et al. Monitoring tolerance after human liver transplantation. Transpl Immunol 2007;17:83-93.
23. Alex Bishop G, Bertolino PD, Bowen DG, Mc- Caughan GW. Tolerance in liver transplantation. Best Pract Res Clin Gastroenterol 2012;26:73-84.
24. Koyama I, Nadazdin O, Boskovic S, et al. Depletion of CD8 memory T cells for induction of tolerance of a previously transplanted kidney allograft. Am J Transplant 2007;7:1055-61.
25. Kawai T, Cosimi AB, Colvin RB, et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995;59:256-62.
26. Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003;111:1887-95.
27. Chimera (mythology). Wikipedia, the free encyclopedia. Available from: http://en.wikipedia.org/w/index.php?title=Chimera_ (mythology)&oldid=525368151. (Accessed January 3, 2013).
28. Matthes-Martin S, Peters C, Königsrainer A, et al. Successful stem cell transplantation following orthotopic liver transplantation from the same haploidentical family donor in a girl with hemophagocytic lymphohistiocytosis. Blood 2000;96:3997-9.
29. Hadzic N, Pagliuca A, Rela M, et al. Correction of the hyper-IgM syndrome after liver and bone marrow transplantation. N Engl J Med 2000;342:320-4.
30. Kawahara K, Storb R, Sanders J, Petersen FB. Successful allogeneic bone marrow transplantation in a 6.5-year-old male for severe aplastic anemia complicating orthotopic liver transplantation for fulminant non-A-non-B hepatitis. Blood 1991;78:1140-3.
31. Rice HE, Skinner MA, Mahaffey SM, et al. Thymic transplantation for complete DiGeorge syndrome: medical and surgical considerations. J Pediatr Surg 2004;39:1607-15.
32. Posselt AM, Barker CF, Tomaszewski JE, et al. Induction of donor-specific unresponsiveness by intrathymic islet transplantation. Science 1990;249:1293-5.
33. Odorico JS, Barker CF, Posselt AM, Naji A. Induction of donor-specific tolerance to rat cardiac allografts by intrathymic inoculation of bone marrow. Surgery 1992;112:370-7.
34. Roedder S, Gao X, Sarwal MM. The pits and pearls in translating operational tolerance biomarkers into clinical practice. Curr Opin Organ Transplant 2012;17:655-62.
35. Lozano JJ, Pallier A, Martinez-Llordella M, et al. Comparison of transcriptional and blood cellphenotypic markers between operationally tolerant liver and kidney recipients. Am J Transplant 2011;11:1916-26.
36. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008;358:353-61.
37. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J Transplant 2012;12:1133-45.
38. Leventhal J, Abecassis M, Miller J, et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med 2012;4:124-8.
39. Spitzer TR, Sykes M, Tolkoff-Rubin N, et al. Longterm follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Transplantation 2011;91:672-76.
40. Castellaneta A, Thomson AW, Nayyar N, et al. Monitoring the operationally tolerant liver allograft recipient. Curr Opin Organ Transplant 2010;15:28-34.
41. Mazariegos GV. Immunosuppression withdrawal after liver transplantation: what are the next steps? Transplantation 2011;91:697-9.
42. Talisetti A, Hurwitz M, Sarwal M, et al. Analysis of clinical variables associated with tolerance in pediatric liver transplant recipients. Pediatr Transplant 2010;14:976-9.
43. Sánchez-Fueyo A. Identification of tolerant recipients following liver transplantation. Int Immunopharmacol 2010;10:1501-4.
44. Feng S, Ekong UD, Lobritto SJ, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 2012;307:283-93.
45. Gao Z, McAlister VC, Williams GM. Repopulation of liver endothelium by bone-marrow-derived cells. Lancet 2001;357:932-3.
46. Devlin J, Doherty D, Thomson L, et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 1998;27:926-33.
47. Mazariegos GV, Sindhi R, Thomson AW, Marcos A. Clinical tolerance following liver transplantation: long term results and future prospects. Transpl Immunol 2007;17:114-19.
48. Girlanda R, Rela M, Williams R, et al. Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant Proc 2005;37:1708-9.
49. Koshiba T, Ito A, Li Y, et al. [Regulatory T cell based transplant tolerance--freedom from immunosuppression]. Nippon Rinsho 2007;65:557-67. [in Japanese]
50. Mazariegos GV, Reyes J, Marino IR, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997;63:243-9